Evidence map›Paper›PMID 34580086›Full record

ArticleDiabetes2021

Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study.

Jennifer E Nyland, Nazia T Raja-Khan, Kerstin Bettermann, Philippe A Haouzi, Douglas L Leslie, Jennifer L Kraschnewski, Leslie J Parent, Patricia Sue Grigson

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 11 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 11 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jennifer E NylandDepartment of Neural and Behavioral Sciences, Penn State College of Medicine, Hershey, PA psg6@psu.edu jnyland@pennstatehealth.psu.edu.ORCID 0000-0002-4549-3617
Nazia T Raja-KhanDepartment of Neural and Behavioral Sciences, Penn State College of Medicine, Hershey, PA.
Kerstin BettermannDepartment of Neural and Behavioral Sciences, Penn State College of Medicine, Hershey, PA.
Philippe A HaouziDepartment of Neural and Behavioral Sciences, Penn State College of Medicine, Hershey, PA.
Douglas L LeslieDepartment of Neural and Behavioral Sciences, Penn State College of Medicine, Hershey, PA.
Jennifer L KraschnewskiDepartment of Neural and Behavioral Sciences, Penn State College of Medicine, Hershey, PA.
Leslie J ParentDepartment of Neural and Behavioral Sciences, Penn State College of Medicine, Hershey, PA.
Patricia Sue GrigsonDepartment of Neural and Behavioral Sciences, Penn State College of Medicine, Hershey, PA psg6@psu.edu jnyland@pennstatehealth.psu.edu.
Penn State Milton S. Hershey Medical Center · US

Funding

Penn State Clinical and Translational Science InstituteUL1TR002014 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KRASCHNEWSKI, JENNIFER L. · 2016 to 2025
$33.7M
Drugs of Abuse and Learned Aversions: Solving a ParadoxR37DA009815 · NIDA · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI GRIGSON, PATRICIA SUE · 2012 to 2020
$2.9M
NCATS NIH HHS UL1 TR002014NIDA NIH HHS R37 DA009815
6 · The paper itself

Abstract

Patients with type 2 diabetes mellitus (T2DM) are at increased risk of severe coronavirus disease 2019 (COVID-19) outcomes possibly because of dysregulated inflammatory responses. Glucose-regulating medications, such as glucagon-like peptide 1 receptor (GLP-1R) agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and pioglitazone, are known to have anti-inflammatory effects that may improve outcomes in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a multinational retrospective cohort study, we used the TriNetX COVID-19 Research Network of 56 large health care organizations to examine these medications in relation to the incidence of hospital admissions, respiratory complications, and mortality within 28 days after a COVID-19 diagnosis. After matching for age, sex, race, ethnicity, BMI, and significant comorbidities, use of GLP-1R agonists and/or pioglitazone was associated with significant reductions in hospital admissions (GLP-1R: 15.7% vs. 23.5%, risk ratio [RR] 0.67 [95% CI 0.57-0.79;

Indexed as

SARS-CoV-2Cohort StudiesCOVID-19Diabetes Mellitus, Type 2FemaleHumansHypoglycemic AgentsMaleRetrospective StudiesHypoglycemic Agents

Identifiers

PMID34580086
PMCPMC8660979
OpenAlexW3201948739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.